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ABSTRACT
Background: The NOTCH signaling pathway may be involved in the survival of 
stem cell-like tumor-initiating cells and contribute to tumor growth. In this phase Ib, 
open-label, multicenter study (NCT01876251), we evaluated PF-03084014, a selective 
gamma-secretase inhibitor in patients with advanced triple-negative breast cancer. 
Methods: The dose-finding part was based on a 2×3 matrix design using the 
modified toxicity probability interval method. Oral PF-03084014 was administered 
twice daily continuously in combination with intravenous docetaxel given on day 1 of 
each 21-day cycle. Primary endpoint was first-cycle dose-limiting toxicity (DLT) for 
the dose-finding part and 6-month progression-free survival (PFS) for the expansion 
cohort treated at the maximum tolerated dose (MTD). Secondary endpoints included 
safety, objective response, and pharmacokinetics of the combination. 
Results and Conclusions: The MTD was estimated to be PF-03084014 100 mg twice 
daily / docetaxel 75 mg/m2. At this dose level, combination treatment was generally 
well tolerated (one DLT, grade 3 diarrhea, among eight DLT-evaluable patients). The 
most common all-grade, treatment-related adverse events reported in all patients (N 
= 29) were neutropenia (90%), fatigue (79%), nausea (72%), leukopenia (69%), 
diarrhea (59%), alopecia (55%), anemia (55%), and vomiting (48%). No effect was 
observed on the pharmacokinetics of docetaxel when administered in combination 
with PF-03084014. Four (16%) of 25 response-evaluable patients achieved a 
confirmed partial response; nine (36%) patients had stable disease, including five 
patients with unconfirmed partial response. In the expansion cohort, median PFS 
was 4.1 (95% CI 1.3-8.1) months (6-month PFS rate 17.1% [95% CI 0.8-52.6%]).
INTRODUCTION
Triple-negative breast cancer (TNBC) is defined by 
the lack of estrogen (ER), progesterone (PR), and human 
epidermal growth factor 2 (HER2) receptors, and it 
accounts for approximately 15% of all breast cancer cases. 
Metastatic TNBC (mTNBC) is associated with a poor 
prognosis [1-3]. TNBCs represent a heterogeneous group 
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of tumors with one common clinical feature: a distinctly 
aggressive nature with higher rates of relapse and shorter 
overall survival in the metastatic setting compared with 
other breast cancer subtypes. Because of the absence of 
well-defined molecular targets, cytotoxic chemotherapy 
is currently the standard treatment option for TNBC. 
Progression on first-line taxane therapy often occurs 
relatively early in mTNBC, with a median progression-free 
survival (PFS) of about 5-6 months [1-3]. Gene expression 
profiling identified six TNBC subtypes displaying unique 
gene expression and ontologies, including two basal-like, 
an immunomodulatory, a mesenchymal, a mesenchymal 
stem-like, and a luminal androgen receptor subtype [4].
It has been hypothesized that the poor response to 
standard treatment seen in patients with TNBC may be 
related to the presence of stem cell-like tumor-initiating 
cells refractory to cytotoxic chemotherapy [3, 5, 6]. The 
NOTCH signaling pathway is involved in the survival 
of stem cell-like tumor-initiating cells, as it plays an 
important role in normal stem cell development and 
differentiation, tumor growth regulation, and malignant 
cell survival [7-11]. Upregulation of the NOTCH pathway 
occurs in mesenchymal and mesenchymal stem-like 
TNBCs. Further, high levels of NOTCH and JAG1 were 
detected in tumors with poor-prognosis features and found 
associated with shorter survival compared to breast cancer 
patients with low tumor levels of NOTCH1 and JAG1 [7-
9].
PF-03084014 is a reversible, noncompetitive, 
selective gamma-secretase inhibitor that blocks the 
NOTCH signaling pathway. It has demonstrated antitumor 
activity in preclinical xenografts models and in patients 
with solid tumors, including advanced thyroid cancer and 
desmoid tumors, and T-cell acute lymphoblastic leukemia 
[12-15]. Combination of PF-03084014 with docetaxel 
significantly increased inhibition of tumor growth in 
patient-derived and cell-line xenograft models of TNBC 
[13], prompting evaluation of this combination for the 
treatment of patients with TNBC.
This phase I study (A8641016) was designed to 
estimate the maximum tolerated dose (MTD) of PF-
03084014 in combination with docetaxel, and evaluate 
safety, tolerability, pharmacokinetics, and antitumor 
activity in patients with advanced TNBC. 
RESULTS
Patients
Twenty-two patients with mTNBC or hormone-
refractory ER/PR-receptor positive breast cancer (two 
ER+ and one PR+), who had received up to two lines of 
prior therapy in the metastatic setting, were treated during 
dose escalation at three dose levels: eight at dose 2b (PF-
Table 1: Patient baseline characteristics
Characteristic
PF-03084014 100 mg 
BID/
docetaxel 75 mg/m2
(n = 15)
PF-03084014 100 mg BID/
docetaxel 100 mg/m2
(n = 3)
PF-03084014 150 mg BID/
docetaxel 75 mg/m2
(n = 11)
All dose levels
(N = 29)
Mean (range) age, years 53 (34-76) 43 (32-64) 46 (27-69) 50 (27-76)
Race, n (%)
   White
   Black
14 (93)
1 (7)
3 (100)
0 
11 (100)
0
28 (97)
1 (3)
ECOG PS, n (%)
   0
   1
9 (60)
6 (40)
1 (33)
2 (67)
8 (73)
3 (27)
18 (62)
11 (38)
Disease, n (%)
   Metastatic 
   Locally recurrent
14 (93)
1 (7)
3 (100)
0
8 (73)
3 (27)
25 (86)
4 (14)
Prior cancer surgery, n (%) 15 (100) 3 (100) 11 (100) 29 (100)
Prior systemic treatmenta, n (%)
   No
   Yes 10 (67)5 (33)
3 (100)
0
7 (64)
4 (36)
20 (69)
9 (31)
Prior radiation therapya, n (%) 
   No
   Yes 11 (73)4 (27)
3 (100)
0
9 (82)
2 (18)
23 (79)
6 (21)
Prior taxane therapy, n (%)
   Yes (adjuvant)
   Yes (neoadjuvant)
   Yes (advanced)
6 (40)
4 (27)
0
1 (33)
0
0
4 (36)
1 (9)
0
11 (38)
5 (17)
0
ECOG PS, Eastern Cooperative Oncology Group performance status.
aPrior anticancer treatment in the advanced/metastatic setting. 
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03084014 100 mg twice daily [BID]/docetaxel 75 mg/m2), 
three at dose 3a (PF-03084014 100 mg BID/docetaxel 100 
mg/m2), and 11 at dose 3b (PF-03084014 150 mg BID/
docetaxel 75 mg/m2) (Supplemental Table S1 and Table 
S2). Seven additional patients with mTNBC were treated 
in first-line at dose 2b (estimated MTD) in the expansion 
phase. All treated patients (N = 29) were evaluable for 
safety, and 25 were evaluable for objective response.
Patient baseline demographic and disease 
characteristics are presented in Table 1. The majority 
of patients had ECOG performance status 0 (62%) and 
metastatic disease (86%), and received combination study 
treatment as first-line therapy (69%) in the advanced/
metastatic setting.
Dose-limiting toxicity (DLT) and safety profile
Patients received treatment according to the study 
design [16] (Supplemental Information). Of 22 DLT-
evaluable patients, one (13%) patient at dose 2b, one 
(33%) patient at dose 3a, and four (36%) patients at dose 
3b experienced DLTs, including grade 3 diarrhea (dose 
2b); grade 3 diarrhea (dose 3a); and grade 3 dehydration, 
grade 3 nausea, grade 4 febrile neutropenia, and grade 
5 septic shock (dose 3b) (Supplemental Table S2). All 
grade 3-4 DLTs resolved following dose reduction of 
PF-03084014 and docetaxel. Only three patients were 
treated at dose 3a due to concerns related to potential 
toxicity of treatment with docetaxel 100 mg. The patient, 
who died of septic shock at dose 3b, had developed grade 
4 neutropenia 7 days after starting study combination 
treatment, indicating an event potentially related to 
docetaxel-induced bone marrow toxicity. A second, 
non-treatment-related death was reported at dose 2b 
in a 67-year-old patient who experienced respiratory 
distress and fatal disease progression. The MTD for the 
combination, defined as the highest tested dose level with 
a DLT rate < 0.33, was estimated to be PF-03084014 100 
mg BID/docetaxel 75 mg/m2 based on the DLTs observed 
at each dose level.
The most common all-grade, treatment-related 
adverse events (AEs) for the combination of PF-
03084014 with docetaxel reported in all patients (N 
= 29) were neutropenia (90%), fatigue (79%), nausea 
(72%), leukopenia (69%), diarrhea (59%), alopecia 
(55%), anemia (55%), and vomiting (48%) (Table 2). PF-
03084014/docetaxel combination treatment-related grade 
3-4 neutropenia was observed in 25 (86%) patients, grade 
Table 2: Treatment-related adverse events occurring in more than 20% of patients (N = 29)a
Adverse event Grade 1n (%)
Grade 2
n (%)
Grade 3b
n (%)
Grade 4
n (%)
All grades 
n (%)
Neutropeniac 0 1 (3) 1 (3) 24 (83) 26 (90)
Fatigue 6 (21) 15 (52) 2 (7) 0 23 (79)
Nausea 12 (41) 7 (24) 2 (7) 0 21 (72)
Leukopeniad 0 1 (3) 13 (45) 6 (21) 20 (69)
Diarrhea 5 (17) 9 (31) 3 (10) 0 17 (59)
Alopecia 9 (31) 7 (24) 0 0 16 (55)
Anemia 7 (24) 8 (28) 1 (3) 0 16 (55)
Vomiting 9 (31) 4 (14) 1 (3) 0 14 (48)
Mucosal inflammation 8 (28) 4 (14) 1 (3) 0 13 (45)
Rashe 8 (28) 5 (17.2) 0 0 13 (45)
Hypophosphatemia 3 (10) 4 (14) 4 (14) 0 11 (38)
Febrile neutropenia 0 0 2 (7) 6 (21) 8 (28)
Thrombocytopeniaf 5 (17) 4 (14) 0 0 9 (31) 
Pyrexia 7 (24) 0 0 0 7 (24)
Stomatitis 3 (10) 4 (14) 0 0 7 (24)
Constipation 5 (17) 1 (3) 0 0 6 (21)
Decreased appetite 2 (7) 4 (14) 0 0 6 (21)
Headache 5 (17) 1 (3) 0 0 6 (21)
Proteinuria 2 (7) 4 (14) 0 0 6 (21)
a‘Treatment-related’ indicates that the adverse event has been related to PF-03084014 and/or docetaxel.
bThree patients developed grade 3 pneumonia, and one patient each experienced aspartate aminotransferase elevation, 
dehydration, hyponatremia, colitis, hypokalemia, prolonged prothrombin time, and decreased performance status (all grade 
3). One grade 5 treatment-related adverse event (septic shock) was reported in a patient who received PF-03084014 150 mg 
BID/docetaxel 75 mg/m2.
cIncludes neutropenia and decreased neutrophil count.
dIncludes leukopenia and decreased white blood cell count.
eIncludes rash, erythematous rash, maculopapular rash, acne, and dermatitis acneiform.
fIncludes thrombocytopenia and decreased platelet count.
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Figure 1: Median concentration-time profiles for docetaxel A. and PF-03084014 B.
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3-4 leukopenia in 19 (66%) patients, and grade 3-4 febrile 
neutropenia in eight (28%) patients; no treatment-related 
grade ≥ 3 thrombocytopenia was reported. Other grade 
3-4 combination treatment-related AEs noted included 
fatigue, nausea, diarrhea, anemia, vomiting, mucosal 
inflammation, and hypophosphatemia (Table 2). At the 
MTD, the most frequently reported non-hematologic grade 
3-4 laboratory abnormalities were hypophosphatemia 
(33%) and hypokalemia (13%).
The majority (72%) of patients discontinued PF-
03084014 due to disease progression. Four patients 
permanently discontinued PF-03084014 owing to a 
treatment-related AE: one patient (dose 3a) due to 
grade 3 vomiting and three patients (dose 3b) due to 
grade 2 fatigue, grade 3 pneumonia, and grade 4 febrile 
neutropenia (n = 1 each). Overall, median duration of 
treatment was four (range, 1-12) cycles for all patients and 
four (range, 2-12) cycles at the MTD.
Pharmacokinetics
No effect was observed on the pharmacokinetics 
of docetaxel when administered in combination with PF-
03084014 (Figure 1A). Median serum concentration-time 
profiles of PF-03084014 alone or in combination with 
docetaxel, at the MTD, are shown in Figure 1B. A lower, 
transient exposure to PF-03084014 was observed on days 
in which it was dosed in combination with docetaxel. At 
the MTD, maximum mean observed serum concentration 
of PF-03084014 was 963 ng/ml when administered alone 
and 950 ng/ml in combination with docetaxel.
Antitumor activity
Best change in target lesions from baseline for 
each response-evaluable patient is shown in Figure 2A. 
Four (16%; 95% CI 4.5-36.1%) of 25 response-evaluable 
patients achieved a confirmed partial response, with 
response duration as shown in Figure 2B. Two of these 
patients received the combination at the MTD, and one 
had been previously treated with paclitaxel in the adjuvant 
setting. Nine (36%) patients had stable disease, including 
five patients with unconfirmed partial response. Eleven 
(44%) patients had best overall response of progressive 
disease (Supplementary Table S3). In the expansion 
cohort, median PFS was 4.1 (95% CI 1.3-8.1) months, 
with a 6-month PFS rate of 17.1% (95% CI 0.8-52.6%). 
DISCUSSION
We report here the results from the first phase I trial 
of the novel gamma-secretase inhibitor PF-03084014 
in combination with docetaxel in patients with locally 
advanced or metastatic TNBC. Results from preclinical 
studies had demonstrated antitumor activity of this 
combination in xenograft models of TNBC [13].
Following dose escalation/de-escalation of either 
drug, the MTD for the combination in patients with TNBC 
was estimated to be PF-03084014 100 mg BID plus 
docetaxel 75 mg/m2. At the estimated MTD, combination 
treatment was generally well tolerated: one DLT, grade 
3 diarrhea, was noted in one of the eight DLT-evaluable 
patients treated at this dose level. At higher doses, a 
patient in the PF-03084014 150 mg BID/docetaxel 75 
mg/m2 cohort C experienced grade 5 treatment-related 
septic shock, potentially related to docetaxel-induced 
neutropenia. The plasma exposure of docetaxel for this 
patient was greater than the mean exposure of the group. 
No unexpected toxicities were observed compared to 
results of prior studies conducted with single-agent PF-
03084014 in patients with solid tumors or hematologic 
malignancies [14, 15] or with docetaxel [1]. The 
most frequent treatment-related AEs reported for the 
combination of PF-03084014 and docetaxel across dose 
levels were neutropenia, fatigue, nausea, leukopenia, 
diarrhea, alopecia, anemia, and vomiting. The non-
hematologic events were generally mild to moderate in 
severity with only grade 3 diarrhea reported frequently. 
Treatment with PF-03084014 in combination with 
docetaxel was not limited by severe diarrhea, as opposed 
to what was observed with other drugs from the same 
class, MK-0752 and RO4929097, administered as single 
agents [17, 18]. In addition, development of squamous 
cell skin cancers was not observed after treatment with 
PF-03084014 either in combination with docetaxel or as a 
single agent [14].
No effect was observed in this study on the 
pharmacokinetics of docetaxel when administered in 
combination with PF-03084014. A transient decrease in 
exposure was noted for PF-03084014 during the days in 
which it was administered in combination with docetaxel. 
Prophylactic administration of dexamethasone from day 
-1 to 2 of each treatment cycle may potentially explain 
this lower exposure observed for PF-03084014 on the 
combination dosing day, resulting from an effect on 
metabolism and drug transport processes [19-21], but 
no clinical impact is foreseen because of continuous PF-
03084014 administration. 
Four (16%) patients had a confirmed partial 
response in first-line treatment of advanced disease; nine 
(36%) patients achieved stable disease as best response, 
including five patients with unconfirmed partial response. 
The overall response rate observed in this study appears 
low, potentially reflecting the limited number of patients 
treated in first-line with the combination at the MTD. In 
addition, three of the patients treated in first-line at the 
estimated MTD had a dose reduction of PF-03084014 
and/or docetaxel. Previous results of phase I studies 
conducted with the gamma-secretase inhibitor RO4929097 
Oncotarget2325www.impactjournals.com/oncotarget
Figure 2: Best tumor size change from baseline A. Duration of response to treatment with PF-03084014 and docetaxel B. PR, 
partial response; PD, progressive disease; SD, stable.
Oncotarget2326www.impactjournals.com/oncotarget
in combination with gemcitabine or capecitabine showed 
limited antitumor activity in patients with advanced 
solid malignancies [22, 23]. One (6%) patient with 
nasopharyngeal cancer had a partial response following 
treatment with the RO4929097/gemcitabine combination 
at a dose above the recommended phase II dose [22]. 
Three (10%) patients with colon or cervical cancer 
had a partial response to the RO4929097/capecitabine 
combination [23].
CONCLUSIONS
Treatment of patients with locally advanced or 
metastatic TNBC with the gamma-secretase inhibitor PF-
03084014 in combination with docetaxel demonstrated 
a manageable safety profile and limited preliminary 
antitumor activity. The MTD for the combination was 
estimated to be PF-03084014 100 mg BID/docetaxel 75 
mg/m2. 
PATIENTS AND METHODS
Study design and patients
This phase Ib, open-label, multicenter study was 
conducted in patients with advanced TNBC and divided 
into two parts: (1) a dose-finding component in patients 
who had received up to two prior lines of chemotherapy 
for metastatic disease, and (2) an expansion cohort 
restricted to patients treated in the first-line, advanced 
setting at the estimated MTD.
Adult women with advanced/metastatic TNBC 
were eligible for the study if they had documented ER-
negative, PR-negative, and HER2-negative status (dose-
escalation and expansion cohort) or were ER/PR-positive, 
HER2-negative, and were unresponsive to hormonal 
therapy by investigator assessment (dose-escalation). 
Further, eligible patients were required to have at least one 
measurable lesion by RECIST version 1.1 criteria, Eastern 
Cooperative Oncology Group (ECOG) performance 
status 0 or 1; and adequate renal, liver, and bone marrow 
function. 
Patients were excluded if they had symptomatic 
brain metastases requiring steroids, had received systemic 
anticancer treatment within 3 weeks of study entry (6 
months for taxanes), had been previously treated with 
a gamma-secretase inhibitor or NOTCH signaling 
inhibitor, had a corrected QT (QTc) interval > 470 msec, 
or had current use or anticipated need for treatment with 
moderate/strong cytochrome P450 (CYP) 3A4 inhibitors 
or strong CYP3A4 inducers. Further, patients who were 
candidates for resection or radiation therapy with curative 
intent were not eligible.
Approval was obtained from the ethics committees 
of the participating institutions. Patients gave written 
informed consent. The study (NCT01876251) followed the 
Declaration of Helsinki and the International Conference 
on Harmonization Good Clinical Practice guidelines.
The primary endpoint was first-cycle DLT 
attributable to PF-03084014 in combination with docetaxel 
for the dose-finding part of the study and PFS at 6 months 
for the expansion cohort. Hematologic DLT included grade 
4 neutropenia lasting > 7 days, febrile neutropenia, grade ≥ 
3 neutropenic infection, grade ≥ 3 thrombocytopenia with 
bleeding, and grade 4 thrombocytopenia without bleeding, 
if attributable to PF-03084014 in combination with 
docetaxel. Non-hematologic DLT included grade ≥ 3 AEs 
if maximally treated; grade 3 QTc prolongation ( > 500 
msec) persisting after correction of any reversible causes; 
dose delay of 2 weeks due to treatment-related AEs; and 
failure to deliver at least 80% of the planned dose in first 
cycle due to treatment-related AEs, if attributable to PF-
03084014 in combination with docetaxel. Secondary 
study endpoints were safety, objective response, duration 
of response, and pharmacokinetics of PF-03084014 in 
combination with docetaxel.
Study treatment
PF-03084014 was administered orally twice 
daily (BID) continuously in combination with 
docetaxel given intravenously on day 1 of each 21-
day cycle. Steroid premedication was given from day 
-1 to day 2 of each cycle, as required for docetaxel 
administration. Administration of PF-03084014 in the 
dose-finding component started on day 2 of cycle 1 for 
pharmacokinetics evaluation purposes. In the expansion 
cohort, patients received PF-03084014 and docetaxel at 
the estimated MTD starting on day 1 of each 21-day cycle, 
with no specific timing requirement for the administration 
of PF-03084014 relative to docetaxel. Study treatment 
was given until disease progression, patient withdrawal, or 
unacceptable toxicity. Treatment with granulocyte-colony 
stimulating factor (G-CSF) was allowed in patients with 
neutropenia. Prophylactic use of G-CSF was permitted 
only after cycle 1.
Study assessments
AEs were continuously monitored and graded for 
severity using the National Cancer Institute Common 
Terminology Criteria for Adverse Events (CTCAE) 
version 3.0.
Antitumor activity was assessed by computed 
tomography or magnetic resonance imaging and bone 
scans at baseline, every 6 weeks, until disease progression 
or death, patient refusal, start of another anticancer 
treatment, or until 1 year from cycle 1, day 1, of last 
enrolled patient whichever occurred first, using RECIST 
version 1.1. 
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Blood samples to determine the pharmacokinetics 
of PF-03084014 were collected on days 2, 8, and 21 (days 
1 and 21 in the expansion cohort) of cycle 1, and on day 
1 of subsequent cycles. In the dose-finding component, 
blood samples were collected on day 1 of cycles 1 and 2 to 
evaluate the pharmacokinetics of docetaxel. Samples were 
analyzed for PF-03084014 and docetaxel concentrations 
using validated analytical methods.
Statistical methods
Dose escalation/de-escalation followed a 2×3 
matrix design with the modified toxicity probability 
interval method [16] (mTPI, see Supplemental Methods) 
using doses of PF-03084014 and docetaxel shown in 
Supplemental Table S1. The estimated MTD was defined 
as the highest tested dose level with estimated DLT rate 
< 0.33. 
The objective response rate was summarized with 
exact two-sided 95% confidence interval (CI) calculated 
using a method based on the F distribution. PFS was 
summarized by the Kaplan-Meier method with 95% CI 
for the median calculated using the Brookmeier-Crowley 
method. 
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